Therapeutic and Diagnostic Applications of Magnetic Nanoparticles in Cancer

Abstract

Magnetic nanoparticles (MNPs) have emerged as a promising tool in cancer theranostics, which combines therapeutic and diagnostic strategies in a single platform. These nanoparticles, typically composed of iron oxide or other magnetic materials, offer unique advantages in cancer management, such as targeted drug delivery, imaging, and real-time monitoring of therapeutic efficacy. MNPs can be functionalized with targeting ligands such as antibodies, peptides, or small molecules to enhance their selectivity for cancer cells, thereby reducing off-target effects and minimizing toxicity. In addition to their therapeutic potential, MNPs enable advanced diagnostic techniques, particularly in magnetic resonance imaging (MRI) and hyperthermia-based treatments. As MRI contrast agents, MNPs enable high-resolution imaging for precise tumour localization and the monitoring of disease progression. Moreover, when subjected to an alternating magnetic field, MNPs can induce localized hyperthermia, effectively killing cancer cells through heat-induced cytotoxicity while sparing surrounding healthy tissue. The dual functionality of MNPs makes them ideal candidates for cancer theranostic applications, enabling the simultaneous diagnosis and treatment of tumours. Despite their potential, several challenges remain in the development of MNPs for clinical use, including issues related to biocompatibility, stability, scalability, and regulatory approval. Furthermore, the optimal size, surface modification, and drug release mechanisms of MNPs must be carefully designed to maximise therapeutic efficacy. Nevertheless, the integration of MNPs in cancer theranostics represents a promising area of research, with the potential to fundamentally change the personalized treatment of cancer by offering more effective, targeted, and non-invasive options.